Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced BRAF-mutant Cancers 1

Interventions

Fulvestrant 3Everolimus 3Cetuximab 3PX-866 2Alpelisib 2venetoclax 1tivozanib 1tipifarnib 1serabelisib 1sapanisertib 1ribociclib 1pembrolizumab 1palbociclib 1neratinib 1exemestane 1cemiplimab 1abemaciclib 1Trimetazidine 1Tamoxifen 1STX-478 1Metformin 1Letrozole 1Irinotecan 1Imlunestrant 1Gemcitabine 1Docetaxel 1Capecitabine 1CB-839 1CA-4948 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Hereditary Sensory and Autonomic Neuropathies × PX-866 × Clear all
NCT01204099 2018-05-16

Study of PX-866 and Docetaxel in Solid Tumors

Seagen Inc.

Phase 1/2 Completed
223 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT01252628 2018-05-16

Phase 1 and 2 Study of PX-866 and Cetuximab

Seagen Inc.

Phase 1/2 Completed
178 enrolled
Gastrointestinal

Carcinoma, Squamous Cell, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡